{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:20:08Z","timestamp":1758709208313,"version":"3.37.3"},"reference-count":95,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T00:00:00Z","timestamp":1554854400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute of Drug Abuse","doi-asserted-by":"crossref","award":["RO1DA036335"],"award-info":[{"award-number":["RO1DA036335"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0213409","type":"journal-article","created":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T18:14:16Z","timestamp":1554920056000},"page":"e0213409","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ancestral sequences from an elite neutralizer proximal to the development of neutralization resistance as a potential source of HIV vaccine immunogens"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6521-534X","authenticated-orcid":true,"given":"Kathryn A.","family":"Mesa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terri","family":"Wrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christos J.","family":"Petropoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant H.","family":"Pogson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerardo","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara M.","family":"O\u2019Rourke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faruk","family":"Sinangil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus A.","family":"Conant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip W.","family":"Berman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,4,10]]},"reference":[{"issue":"14","key":"ref1","doi-asserted-by":"crossref","first-page":"7337","DOI":"10.1128\/JVI.00110-09","article-title":"Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm","volume":"83","author":"MD Simek","year":"2009","journal-title":"Journal of virology"},{"issue":"8","key":"ref2","doi-asserted-by":"crossref","first-page":"e1001028","DOI":"10.1371\/journal.ppat.1001028","article-title":"A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals","volume":"6","author":"LM Walker","year":"2010","journal-title":"PLoS pathogens"},{"issue":"7365","key":"ref3","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature10373","article-title":"Broad neutralization coverage of HIV by multiple highly potent antibodies","volume":"477","author":"LM Walker","year":"2011","journal-title":"Nature"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.immuni.2012.08.012","article-title":"Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies","volume":"37","author":"PD Kwong","year":"2012","journal-title":"Immunity"},{"issue":"6151","key":"ref5","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1241144","article-title":"Antibodies in HIV-1 vaccine development and therapy","volume":"341","author":"F Klein","year":"2013","journal-title":"Science"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.virol.2012.10.004","article-title":"Broadly neutralizing antibodies against HIV-1: templates for a vaccine","volume":"435","author":"MJ van Gils","year":"2013","journal-title":"Virology"},{"issue":"46","key":"ref7","doi-asserted-by":"crossref","first-page":"18921","DOI":"10.1073\/pnas.1214785109","article-title":"Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo","volume":"109","author":"B Moldt","year":"2012","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"10","key":"ref8","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1084\/jem.20132494","article-title":"Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques","volume":"211","author":"M Shingai","year":"2014","journal-title":"Journal of Experimental Medicine"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"16199","DOI":"10.1038\/nmicrobiol.2016.199","article-title":"An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability","volume":"2","author":"MJ Van Gils","year":"2017","journal-title":"Nature microbiology"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/ni0304-233","article-title":"HIV vaccine design and the neutralizing antibody problem","volume":"5","author":"DR Burton","year":"2004","journal-title":"Nature immunology"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3390\/vaccines1040497","article-title":"Envelope glycoprotein trimers as HIV-1 vaccine immunogens","volume":"1","author":"QJ Sattentau","year":"2013","journal-title":"Vaccines"},{"issue":"37","key":"ref12","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1016\/j.vaccine.2009.06.037","article-title":"Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1","volume":"27","author":"YK Kang","year":"2009","journal-title":"Vaccine"},{"issue":"6244","key":"ref13","doi-asserted-by":"crossref","first-page":"aac4223","DOI":"10.1126\/science.aac4223","article-title":"HIV-1 neutralizing antibodies induced by native-like envelope trimers","volume":"349","author":"RW Sanders","year":"2015","journal-title":"Science"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.virol.2006.10.032","article-title":"A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120","volume":"360","author":"S Beddows","year":"2007","journal-title":"Virology"},{"issue":"30","key":"ref15","doi-asserted-by":"crossref","first-page":"12111","DOI":"10.1073\/pnas.1204533109","article-title":"HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120","volume":"109","author":"JM Kovacs","year":"2012","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"4","key":"ref16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.celrep.2015.03.047","article-title":"Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design","volume":"11","author":"SK Sharma","year":"2015","journal-title":"Cell reports"},{"issue":"9","key":"ref17","doi-asserted-by":"crossref","first-page":"e1003618","DOI":"10.1371\/journal.ppat.1003618","article-title":"A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP. 664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies","volume":"9","author":"RW Sanders","year":"2013","journal-title":"PLoS pathogens"},{"issue":"8","key":"ref18","doi-asserted-by":"crossref","first-page":"e43903","DOI":"10.1371\/journal.pone.0043903","article-title":"Glycoform and net charge heterogeneity in gp120 immunogens used in HIV vaccine trials","volume":"7","author":"B Yu","year":"2012","journal-title":"PLoS One"},{"issue":"14","key":"ref19","doi-asserted-by":"crossref","first-page":"8812","DOI":"10.1128\/JVI.79.14.8812-8827.2005","article-title":"Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1","volume":"79","author":"S Beddows","year":"2005","journal-title":"Journal of virology"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1089\/aid.2005.21.58","article-title":"Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. AIDS Research &","volume":"21","author":"M Kim","year":"2005","journal-title":"Human Retroviruses"},{"issue":"18","key":"ref21","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.vaccine.2014.02.001","article-title":"Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer","volume":"32","author":"JP Nkolola","year":"2014","journal-title":"Vaccine"},{"key":"ref22","first-page":"01653","article-title":"Murine antibody responses to cleaved soluble HIV-1 envelope trimers are highly restricted in specificity","volume":"JVI","author":"JK Hu","year":"2015","journal-title":"Journal of virology"},{"issue":"7","key":"ref23","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.cell.2015.11.056","article-title":"Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes","volume":"163","author":"SW De Taeye","year":"2015","journal-title":"Cell"},{"issue":"6","key":"ref24","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1128\/JVI.02380-15","article-title":"Immunogenicity of a prefusion HIV-1 envelope trimer in complex with a quaternary-structure-specific antibody","volume":"90","author":"C Cheng","year":"2016","journal-title":"Journal of virology"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1128\/JVI.02036-08","article-title":"Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection","volume":"83","author":"DN Sather","year":"2009","journal-title":"Journal of virology"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1128\/JVI.01992-08","article-title":"Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals","volume":"83","author":"Y Li","year":"2009","journal-title":"Journal of virology"},{"issue":"8","key":"ref27","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nm.1949","article-title":"Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine","volume":"15","author":"L Stamatatos","year":"2009","journal-title":"Nature medicine"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"e1005369","DOI":"10.1371\/journal.ppat.1005369","article-title":"Broadly neutralizing antibody responses in a large longitudinal sub-Saharan HIV primary infection cohort","volume":"12","author":"E Landais","year":"2016","journal-title":"PLoS pathogens"},{"issue":"7","key":"ref29","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1073\/pnas.0630530100","article-title":"Rapid evolution of the neutralizing antibody response to HIV type 1 infection","volume":"100","author":"DD Richman","year":"2003","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"ref30","article-title":"HIV-1 neutralization breadth develops incrementally over 4 years and is associated with CD4+ T cell decline and high viral load during acute infection","author":"ES Gray","year":"2011","journal-title":"Journal of virology"},{"issue":"12","key":"ref31","doi-asserted-by":"crossref","first-page":"6187","DOI":"10.1128\/JVI.00239-07","article-title":"Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection","volume":"81","author":"ES Gray","year":"2007","journal-title":"Journal of virology"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"e1001251","DOI":"10.1371\/journal.ppat.1001251","article-title":"Characteristics of the earliest cross-neutralizing antibody response to HIV-1","volume":"7","author":"I Mikell","year":"2011","journal-title":"PLoS pathogens"},{"issue":"6929","key":"ref33","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","article-title":"Antibody neutralization and escape by HIV-1","volume":"422","author":"X Wei","year":"2003","journal-title":"Nature"},{"issue":"11","key":"ref34","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1038\/nm.2985","article-title":"Evolution of an HIV glycan\u2013dependent broadly neutralizing antibody epitope through immune escape","volume":"18","author":"PL Moore","year":"2012","journal-title":"Nature medicine"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"9586","DOI":"10.1128\/JVI.00141-06","article-title":"HIV-1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection and these modifications affect antibody neutralization sensitivity","volume":"80","author":"M Sagar","year":"2006","journal-title":"J Virol"},{"issue":"21","key":"ref36","doi-asserted-by":"crossref","first-page":"11200","DOI":"10.1128\/JVI.00790-10","article-title":"Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus","volume":"84","author":"SM O\u2019Rourke","year":"2010","journal-title":"Journal of virology"},{"key":"ref37","first-page":"00696","article-title":"A short segment of the HIV-1 gp120 V1\/V2 region is a major determinant of resistance to V1\/V2 neutralizing antibodies","volume":"JVI","author":"NA Doria-Rose","year":"2012","journal-title":"Journal of virology"},{"issue":"21","key":"ref38","doi-asserted-by":"crossref","first-page":"11200","DOI":"10.1128\/JVI.00790-10","article-title":"Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus","volume":"84","author":"SM O'Rourke","year":"2010","journal-title":"Journal of virology"},{"key":"ref39","article-title":"Sequences in gp41, the CD4 Binding Site, and the V2 Domain Regulate Sensitivity and Resistance to Broadly Neutralizing Antibodies","author":"SM O\u2019Rourke","year":"2012","journal-title":"Journal of virology"},{"issue":"3","key":"ref40","doi-asserted-by":"crossref","first-page":"e0119608","DOI":"10.1371\/journal.pone.0119608","article-title":"Glycans flanking the hypervariable connecting peptide between the A and B strands of the V1\/V2 domain of HIV-1 gp120 confer resistance to antibodies that neutralize CRF01_AE viruses","volume":"10","author":"SM O\u2019Rourke","year":"2015","journal-title":"PLoS One"},{"issue":"7446","key":"ref41","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nature12053","article-title":"Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus","volume":"496","author":"H-X Liao","year":"2013","journal-title":"Nature"},{"issue":"3","key":"ref42","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2014.06.022","article-title":"Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies","volume":"158","author":"F Gao","year":"2014","journal-title":"Cell"},{"issue":"7498","key":"ref43","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature13036","article-title":"Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies","volume":"509","author":"NA Doria-Rose","year":"2014","journal-title":"Nature"},{"issue":"11","key":"ref44","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/nm.3963","article-title":"Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies","volume":"21","author":"JN Bhiman","year":"2015","journal-title":"Nature medicine"},{"issue":"2","key":"ref45","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cell.2016.02.022","article-title":"Maturation pathway from germline to broad HIV-1 neutralizer of a CD4-mimic antibody","volume":"165","author":"M Bonsignori","year":"2016","journal-title":"Cell"},{"issue":"5","key":"ref46","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.immuni.2017.11.002","article-title":"HIV envelope glycoform heterogeneity and localized diversity govern the initiation and maturation of a V2 apex broadly neutralizing antibody lineage","volume":"47","author":"E Landais","year":"2017","journal-title":"Immunity"},{"issue":"381","key":"ref47","doi-asserted-by":"crossref","first-page":"eaai7514","DOI":"10.1126\/scitranslmed.aai7514","article-title":"Staged induction of HIV-1 glycan\u2013dependent broadly neutralizing antibodies","volume":"9","author":"M Bonsignori","year":"2017","journal-title":"Science translational medicine"},{"issue":"5197","key":"ref48","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1126\/science.7824947","article-title":"HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy","volume":"267","author":"JM Coffin","year":"1995","journal-title":"Science"},{"issue":"5","key":"ref49","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00126334-200404150-00005","article-title":"Drug-Resistant Variants That Evolve During Nonsuppressive Therapy Persist in HIV-1\u2013Infected Peripheral Blood Mononuclear Cells After Long-Term Highly Active Antiretroviral Therapy","volume":"35","author":"C Verhofstede","year":"2004","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"issue":"5341","key":"ref50","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy","volume":"278","author":"D Finzi","year":"1997","journal-title":"Science"},{"issue":"51","key":"ref51","doi-asserted-by":"crossref","first-page":"18514","DOI":"10.1073\/pnas.0504658102","article-title":"Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection","volume":"102","author":"SD Frost","year":"2005","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"5950","key":"ref52","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1126\/science.1178746","article-title":"Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target","volume":"326","author":"LM Walker","year":"2009","journal-title":"Science"},{"issue":"12","key":"ref53","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.1128\/JVI.00093-06","article-title":"Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses","volume":"80","author":"SG Deeks","year":"2006","journal-title":"Journal of virology"},{"issue":"4","key":"ref54","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1086\/654816","article-title":"Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine","volume":"202","author":"P Gilbert","year":"2010","journal-title":"The Journal of infectious diseases"},{"issue":"12","key":"ref55","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/bioinformatics\/bts199","article-title":"Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data","volume":"28","author":"M Kearse","year":"2012","journal-title":"Bioinformatics"},{"issue":"10","key":"ref56","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1093\/molbev\/msr121","article-title":"MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods","volume":"28","author":"K Tamura","year":"2011","journal-title":"Molecular biology and evolution"},{"issue":"8","key":"ref57","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/bioinformatics\/17.8.754","article-title":"MRBAYES: Bayesian inference of phylogenetic trees","volume":"17","author":"JP Huelsenbeck","year":"2001","journal-title":"Bioinformatics"},{"issue":"2","key":"ref58","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1128\/AAC.00853-06","article-title":"Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism","volume":"51","author":"JM Whitcomb","year":"2007","journal-title":"Antimicrobial agents and chemotherapy"},{"issue":"5","key":"ref59","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1469-0691.2010.03350.x","article-title":"Analysis of co\u2010receptor usage of circulating viral and proviral HIV genome quasispecies by ultra\u2010deep pyrosequencing in patients who are candidates for CCR5 antagonist treatment","volume":"17","author":"I Abbate","year":"2011","journal-title":"Clinical microbiology and infection"},{"key":"ref60","first-page":"M114","article-title":"HIV-1 envelope proteins and V1\/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1","volume":"jbc","author":"JF Morales","year":"2014","journal-title":"Journal of Biological Chemistry"},{"issue":"5","key":"ref61","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/aid.1994.10.585","article-title":"Adhesion mediated by intercellular adhesion molecule 1 attenuates the potency of antibodies that block HIV-1 gp160-dependent syncytium formation","volume":"10","author":"PW Berman","year":"1994","journal-title":"AIDS research and human retroviruses"},{"issue":"2","key":"ref62","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1086\/514055","article-title":"Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers","volume":"176","author":"PW Berman","year":"1997","journal-title":"Journal of Infectious Diseases"},{"issue":"8","key":"ref63","doi-asserted-by":"crossref","first-page":"e12076","DOI":"10.1371\/journal.pone.0012076","article-title":"Comparative immunogenicity of HIV-1 clade C envelope proteins for prime\/boost studies","volume":"5","author":"DH Smith","year":"2010","journal-title":"PLoS One"},{"issue":"4760","key":"ref64","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1126\/science.3014647","article-title":"Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein","volume":"233","author":"LA Lasky","year":"1986","journal-title":"Science"},{"issue":"10","key":"ref65","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.1128\/JVI.67.10.6179-6191.1993","article-title":"Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1","volume":"67","author":"GR Nakamura","year":"1993","journal-title":"Journal of virology"},{"issue":"5993","key":"ref66","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1126\/science.1192819","article-title":"Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01","volume":"329","author":"T Zhou","year":"2010","journal-title":"Science"},{"issue":"21","key":"ref67","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","article-title":"Effect of HIV antibody VRC01 on viral rebound after treatment interruption","volume":"375","author":"KJ Bar","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"ref68","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nsmb.2600","article-title":"Structural basis for diverse N-glycan recognition by HIV-1\u2013neutralizing V1\u2013V2\u2013directed antibody PG16","volume":"20","author":"M Pancera","year":"2013","journal-title":"Nature structural & molecular biology"},{"issue":"1","key":"ref69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0b013e318074eb5a","article-title":"Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals","volume":"46","author":"B Schweighardt","year":"2007","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"issue":"7377","key":"ref70","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/nature10696","article-title":"Structure of HIV-1 gp120 V1\/V2 domain with broadly neutralizing antibody PG9","volume":"480","author":"JS McLellan","year":"2011","journal-title":"Nature"},{"issue":"6207","key":"ref71","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/337525a0","article-title":"Designing CD4 immunoadhesins for AIDS therapy","volume":"337","author":"DJ Capon","year":"1989","journal-title":"Nature"},{"issue":"16","key":"ref72","doi-asserted-by":"crossref","first-page":"7056","DOI":"10.1073\/pnas.88.16.7056","article-title":"Resistance of primary isolates of human immunodeficiency virus type 1 to soluble CD4 is independent of CD4-rgp120 binding affinity","volume":"88","author":"A Ashkenazi","year":"1991","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"1","key":"ref73","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.virol.2009.11.032","article-title":"Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response","volume":"398","author":"KA Bosch","year":"2010","journal-title":"Virology"},{"issue":"9","key":"ref74","doi-asserted-by":"crossref","first-page":"e1000594","DOI":"10.1371\/journal.ppat.1000594","article-title":"Escape from autologous neutralizing antibodies in acute\/early subtype C HIV-1 infection requires multiple pathways","volume":"5","author":"R Rong","year":"2009","journal-title":"PLoS pathogens"},{"issue":"17","key":"ref75","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1073\/pnas.87.17.6574","article-title":"High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates","volume":"87","author":"ES Daar","year":"1990","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"18","key":"ref76","doi-asserted-by":"crossref","first-page":"10373","DOI":"10.1016\/S0021-9258(18)86956-3","article-title":"Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells","volume":"265","author":"CK Leonard","year":"1990","journal-title":"Journal of Biological Chemistry"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"236ra63","DOI":"10.1126\/scitranslmed.3008104","article-title":"Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV","volume":"6","author":"D Sok","year":"2014","journal-title":"Sci Transl Med"},{"issue":"6","key":"ref78","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.immuni.2015.11.007","article-title":"Affinity maturation of a potent family of HIV antibodies is primarily focused on accommodating or avoiding glycans","volume":"43","author":"F Garces","year":"2015","journal-title":"Immunity"},{"issue":"4","key":"ref79","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1128\/JVI.02187-07","article-title":"The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection","volume":"82","author":"PL Moore","year":"2008","journal-title":"Journal of virology"},{"issue":"7","key":"ref80","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/nsmb.2594","article-title":"Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120","volume":"20","author":"L Kong","year":"2013","journal-title":"Nature structural & molecular biology"},{"key":"ref81","first-page":"1245625","article-title":"Crystal structure of a soluble cleaved HIV-1 envelope trimer","author":"J-P Julien","year":"2013","journal-title":"Science"},{"key":"ref82","first-page":"01352","article-title":"Sequences in gp41, the CD4 Binding Site, and the V2 Domain Regulate Sensitivity and Resistance to Broadly Neutralizing Antibodies","volume":"JVI","author":"SM O\u2019Rourke","year":"2012","journal-title":"Journal of virology"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"7479","DOI":"10.1038\/ncomms8479","article-title":"Glycan clustering stabilizes the mannose patch of HIV-1 and preserves vulnerability to broadly neutralizing antibodies","volume":"6","author":"LK Pritchard","year":"2015","journal-title":"Nature communications"},{"issue":"10","key":"ref84","doi-asserted-by":"crossref","first-page":"e1000955","DOI":"10.1371\/journal.pcbi.1000955","article-title":"Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies","volume":"6","author":"S Gnanakaran","year":"2010","journal-title":"PLoS computational biology"},{"issue":"2","key":"ref85","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.virol.2010.09.031","article-title":"Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120","volume":"409","author":"JL Kirchherr","year":"2011","journal-title":"Virology"},{"issue":"1","key":"ref86","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1742-4690-10-102","article-title":"HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity","volume":"10","author":"TL Van den Kerkhof","year":"2013","journal-title":"Retrovirology"},{"issue":"4","key":"ref87","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.celrep.2018.09.087","article-title":"Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth","volume":"25","author":"K Wagh","year":"2018","journal-title":"Cell Reports"},{"issue":"1","key":"ref88","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/viro.1999.0031","article-title":"Development of bivalent (B\/E) vaccines able to neutralize CCR5-dependent viruses from the United States and Thailand","volume":"265","author":"PW Berman","year":"1999","journal-title":"Virology"},{"issue":"23","key":"ref89","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"S Rerks-Ngarm","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"50","key":"ref90","doi-asserted-by":"crossref","first-page":"20125","DOI":"10.1073\/pnas.1117531108","article-title":"Rapid development of glycan-specific, broad, and potent anti\u2013HIV-1 gp120 neutralizing antibodies in an R5 SIV\/HIV chimeric virus infected macaque","volume":"108","author":"LM Walker","year":"2011","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"4","key":"ref91","doi-asserted-by":"crossref","first-page":"e0196370","DOI":"10.1371\/journal.pone.0196370","article-title":"Glycan modifications to the gp120 immunogens used in the RV144 vaccine trial improve binding to broadly neutralizing antibodies","volume":"13","author":"RC Doran","year":"2018","journal-title":"PloS one"},{"issue":"47","key":"ref92","doi-asserted-by":"crossref","first-page":"E3268","DOI":"10.1073\/pnas.1217207109","article-title":"Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies","volume":"109","author":"H Mouquet","year":"2012","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"7498","key":"ref93","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature13036","article-title":"Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies","volume":"509","author":"NA Doria-Rose","year":"2014","journal-title":"Nature"},{"issue":"4","key":"ref94","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.tim.2014.12.007","article-title":"Virological features associated with the development of broadly neutralizing antibodies to HIV-1","volume":"23","author":"PL Moore","year":"2015","journal-title":"Trends in microbiology"},{"issue":"5","key":"ref95","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nbt.2197","article-title":"B-cell\u2013lineage immunogen design in vaccine development with HIV-1 as a case study","volume":"30","author":"BF Haynes","year":"2012","journal-title":"Nature biotechnology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0213409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T18:17:50Z","timestamp":1663265870000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0213409"}},"subtitle":[],"editor":[{"given":"Heidi E.","family":"Drummer","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,4,10]]},"references-count":95,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0213409","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2019,4,10]]}}}